Asymmetric Dimethylarginine Level in Children Undergoing Bone Marrow Transplantation

Background: Asymmetric dimethylarginine (ADMA) is a toxic, non‐proteinogenic amino acids formed by post‐translational modification and is a uremic toxin that inhibits nitric oxide (NO) production. The aim of this work was to assess the serum level of asymmetric dimethylarginine in children underwent bone marrow transplantation. Methods: This prospective, randomized controlled study has been conducted on 20 children aged 2-18 years underwent bone marrow transplantation (Group I) and 20 healthy control children of matched age and sex (group II). Results: The serum level of ADMA was significantly higher after bone marrow transplantation (p value <0.05). Conclusions: Elevated ADMA level after bone marrow transplantation indicates that endothelial dysfunction is a main complication in those patients.